Oct-13 -
Leukemia Group / Elderly
EORTC 06012 – Gemtuzumab Ozogamycin (GO) combined with standard intensive chemotherapy versus standard intensive chemotherapy alone for induction/consolidation in patients 61 – 75 years old with previously untreated AML : a randomized phase III trial (AML-17) of the EORTC – LG and the GIMEMA-ALWP.
EORTC found that the addition of gentuzumab ozogamicin (GO) prior to standard induction treatment provides no benefit for patients of 61 to 75 years old with acute myelogenous leukemia (AML).